5-[2-[(2R)-1-(3,5-difluorophenyl)-4-oxo-5-[4-oxo-3-(trifluoromethyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-1-yl]pentan-2-yl]-3-pyridinyl]-2-fluorobenzamide;ethyl 2-(3-methyl-4-oxo-5,6-dihydrocyclopenta[d]pyrazol-1-yl)acetate;ethyl 2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetate;2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetic acid
C62H64F6N12O12 — CID 158539569
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[2-[(2R)-1-(3,5-difluorophenyl)-4-oxo-5-[4-oxo-3-(trifluoromethyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-1-yl]pentan-2-yl]-3-pyridinyl]-2-fluorobenzamide;ethyl 2-(3-methyl-4-oxo-5,6-dihydrocyclopenta[d]pyrazol-1-yl)acetate;ethyl 2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetate;2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetic acid
5-[2-[(2R)-1-(3,5-difluorophenyl)-4-oxo-5-[4-oxo-3-(trifluoromethyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-1-yl]pentan-2-yl]-3-pyridinyl]-2-fluorobenzamide;ethyl 2-(3-methyl-4-oxo-5,6-dihydrocyclopenta[d]pyrazol-1-yl)acetate;ethyl 2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetate;2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetic acid (PubChem CID 158539569) has the molecular formula C62H64F6N12O12 and a molecular weight of 1283.25 g/mol. Its IUPAC name is 5-[2-[(2R)-1-(3,5-difluorophenyl)-4-oxo-5-[4-oxo-3-(trifluoromethyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-1-yl]pentan-2-yl]-3-pyridinyl]-2-fluorobenzamide;ethyl 2-(3-methyl-4-oxo-5,6-dihydrocyclopenta[d]pyrazol-1-yl)acetate;ethyl 2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetate;2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetic acid.
Molecular Properties
| Compound Name | 5-[2-[(2R)-1-(3,5-difluorophenyl)-4-oxo-5-[4-oxo-3-(trifluoromethyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-1-yl]pentan-2-yl]-3-pyridinyl]-2-fluorobenzamide;ethyl 2-(3-methyl-4-oxo-5,6-dihydrocyclopenta[d]pyrazol-1-yl)acetate;ethyl 2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetate;2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetic acid |
|---|---|
| PubChem CID | 158539569 |
| Molecular Formula | C62H64F6N12O12 |
| Molecular Weight | 1283.25 g/mol |
| Exact Mass | 1282.47 |
| IUPAC Name | 5-[2-[(2R)-1-(3,5-difluorophenyl)-4-oxo-5-[4-oxo-3-(trifluoromethyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-1-yl]pentan-2-yl]-3-pyridinyl]-2-fluorobenzamide;ethyl 2-(3-methyl-4-oxo-5,6-dihydrocyclopenta[d]pyrazol-1-yl)acetate;ethyl 2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetate;2-(3-methyl-4-oxo-6,7-dihydro-5H-pyrazolo[4,5-c]pyridin-1-yl)acetic acid |
| SMILES | CCOC(=O)Cn1nc(C)c2c1CCC2=O.CCOC(=O)Cn1nc(C)c2c1CCNC2=O.Cc1nn(CC(=O)O)c2c1C(=O)NCC2.NC(=O)c1cc(-c2cccnc2[C@@H](CC(=O)Cn2cc(C(F)(F)F)c3c2CCNC3=O)Cc2cc(F)cc(F)c2)ccc1F |
| InChI | InChI=1S/C31H24F6N4O3.C11H15N3O3.C11H14N2O3.C9H11N3O3/c32-19-9-16(10-20(33)13-19)8-18(28-22(2-1-6-39-28)17-3-4-25(34)23(12-17)29(38)43)11-21(42)14-41-15-24(31(35,36)37)27-26(41)5-7-40-30(27)44;1-3-17-9(15)6-14-8-4-5-12-11(16)10(8)7(2)13-14;1-3-16-10(15)6-13-8-4-5-9(14)11(8)7(2)12-13;1-5-8-6(2-3-10-9(8)15)12(11-5)4-7(13)14/h1-4,6,9-10,12-13,15,18H,5,7-8,11,14H2,(H2,38,43)(H,40,44);3-6H2,1-2H3,(H,12,16);3-6H2,1-2H3;2-4H2,1H3,(H,10,15)(H,13,14)/t18-;;;/m1.../s1 |
| InChIKey | HOIUEZIBDQDDTF-YTNSDAIYSA-N |
| XLogP | 5.84 |
| TPSA | 325.71 Ų |
| H-Bond Donors | 5 |
| H-Bond Acceptors | 19 |
| Rotatable Bonds | 17 |
| Heavy Atoms | 92 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1283.25 |
| LogP ≤ 5 | 5.84 |
| H-Bond Donors ≤ 5 | 5 |
| H-Bond Acceptors ≤ 10 | 19 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 158539569 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.